Skip to content

Study · Non-randomized trial · 1995

2 results

Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.

Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A

Bone1 Oct 1995Cited by 89 (Europe PMC)

PMID8573412 (opens in a new tab)DOI10.1016/s8756-3282(95)00262-6 (opens in a new tab)PepBankPUB-08573412
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with osteoporosis, salmon calcitonin did not significantly increase bone mineral mass at any measured site.

    In plain wordsIn postmenopausal women with osteoporosis, salmon calcitonin did not significantly increase bone mineral mass at any measured site.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeBone mineral mass at measured sites
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 IU/day · intranasal · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    In contrast, intranasal salmon calcitonin failed to increase bone mineral mass significantly at any site.
    2 context sentences
    Summary · context
    Nine centers in Italy enrolled 286 postmenopausal women between the ages of 48 and 76 with spinal bone mineral density > or = 2 SD below adult mean peak in the two-year, double-blind, randomized, placebo-controlled trial.
    Summary · context
    Patients were randomized to one of four treatment arms: double-blind placebo, alendronate 10 mg/day, alendronate 20 mg/day, or open-label intranasal salmon calcitonin 100 IU/day; all patients received 500 mg Ca++ supplements.
  2. 02HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with osteoporosis, salmon calcitonin did not significantly decrease serum alkaline phosphatase, serum osteocalcin, or urinary pyridinolines.

    In plain wordsIn postmenopausal women with osteoporosis, salmon calcitonin did not significantly decrease the three reported biochemical markers of bone turnover.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeBiochemical bone turnover markers
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 IU/day · intranasal · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Both alendronate doses significantly decreased serum alkaline phosphatase, serum osteocalcin, and urinary pyridinolines, markers of bone turnover, whereas placebo and intranasal calcitonin did not.
    2 context sentences
    Summary · context
    Nine centers in Italy enrolled 286 postmenopausal women between the ages of 48 and 76 with spinal bone mineral density > or = 2 SD below adult mean peak in the two-year, double-blind, randomized, placebo-controlled trial.
    Summary · context
    Patients were randomized to one of four treatment arms: double-blind placebo, alendronate 10 mg/day, alendronate 20 mg/day, or open-label intranasal salmon calcitonin 100 IU/day; all patients received 500 mg Ca++ supplements.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.